The Nigerian government has officially commenced the rollout of Lenacapavir a revolutionary long acting injectable drug designed for HIV prevention. This twice yearly injection represents a significant breakthrough in the country’s efforts to combat the HIV epidemic and move closer to ending AIDS as a public health threat by 2030. However health authorities have clearly stated that pregnant women will not be eligible to receive the injection at this stage due to insufficient safety data currently available.
The initial phase of the rollout will cover eight states and the Federal Capital Territory including Anambra, Ebonyi, Gombe, Kwara, Akwa Ibom, Cross River, Benue and the FCT. These locations were strategically selected based on high HIV prevalence rates existing infrastructure readiness and the presence of Global Fund support. Approximately fifty two thousand doses have been secured for the pilot phase with the first batch of over eleven thousand doses already delivered to designated facilities. Distribution to health centers in the selected states is expected to begin shortly following staff training and community sensitization efforts.
Lenacapavir developed by Gilead Sciences and recommended by the World Health Organization offers a highly effective and convenient alternative to daily oral pre exposure prophylaxis pills. Clinical trials have demonstrated near complete protection against HIV infection with some studies reporting up to one hundred percent efficacy among participants. Administered just twice a year the injection is expected to improve adherence rates particularly among individuals who find daily medication challenging while also providing greater privacy and reducing stigma associated with frequent pill taking.
The Federal Government through the National Agency for the Control of AIDS and the Ministry of Health emphasized that Lenacapavir will complement existing prevention tools such as oral PrEP and the long acting injectable Cabotegravir. This expanded choice aims to reach more people at risk including adolescent girls and young women key populations and others in high burden areas. Officials however stressed the importance of using the drug as part of a comprehensive prevention package that includes regular HIV testing counseling and safer sex practices.
The exclusion of pregnant women stems from the need for more robust safety data in this specific population. Health experts noted that while the drug has shown promising results in general trials additional studies are required to fully assess its impact during pregnancy and breastfeeding. Women who are pregnant or planning pregnancy are advised to continue with other approved prevention methods under medical guidance. This cautious approach reflects the government’s commitment to prioritizing safety while introducing innovative health interventions.
This rollout positions Nigeria among a select group of early adopter countries in Africa supported by the Global Fund. Stakeholders believe the initiative could significantly reduce new HIV infections if scaled successfully. Demand for the injection has already surged in anticipation with many Nigerians seeking information on access points. As the program expands authorities plan to monitor uptake effectiveness and any emerging safety signals to inform future nationwide implementation.
The development marks a hopeful step in Nigeria’s HIV response which continues to grapple with an estimated 1.9 million people living with the virus and ongoing new infections especially among vulnerable groups. By introducing Lenacapavir the government aims to strengthen prevention efforts and build greater resilience in the national health system.
